cd7.car/28zeta car t cells
T-Cell Acute Lymphoblastic Leukemia
Explore 76 assets in T-Cell Acute Lymphoblastic Leukemia →Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07220993CT.gov Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells | — | Recruiting | — | — | — |
NCT07070323CT.gov A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies | — | Recruiting | — | — | — |
NCT06316856CT.gov CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies | — | Recruiting | — | — | — |
NCT05909527CT.gov A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma | — | Withdrawn | — | — | — |
NCT05596266CT.gov CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia | — | Unknown | — | — | — |
NCT03690011CT.gov Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells | — | Active Not Recruiting | — | — | — |
NCT03081910CT.gov Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Cell Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| cd7.car/28zeta car t cells (this asset) | Institute of Hematology & Blood Diseases Hospital, China | P1/2 | CCC · 50 |
| Vincristine Sulfate | Children's Oncology Group | P3 | BB |
| Mercaptopurine Anhydrous | SWOG Cancer Research Network | P3 | BB |
| Daunomycin | SWOG Cancer Research Network | P3 | BB |
| Pegaspargase | Children's Oncology Group | P3 | BB |
| Crisantaspase | University of Washington | P3 | BB |
| Cytarabine | SWOG Cancer Research Network | P3 | BB |
| Adriamycin | SWOG Cancer Research Network | P3 | BB |
| Prednisone | Children's Oncology Group | P3 | BB |
+42 more in the T-Cell Acute Lymphoblastic Leukemia cohort
Other indications for cd7.car/28zeta car t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Non-Hodgkin Lymphoma | — | P2 | BB · 66 |
| T-Lymphoblastic Lymphoma | — | P1/2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. cd7.car/28zeta car t cells in T-Cell Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cd7car28zeta-car-t-cells-t-cell-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →